VViking Global Investors is a global investment firm managing over $48 billion in capital across public and private markets. It uses fundamental analysis and long/short strategies, taking long positions in undervalued companies and short positions in overvalued ones, across public equity, private equity, credit, and structured capital. The firm serves institutional investors, high-net-worth individuals, and qualified investors, aiming to generate high risk-adjusted returns. Fees come from management and performance-based charges. The main difference from competitors lies in its emphasis on fundamental, long/short investing across both public and private markets and its broad, globally distributed investment approach.
Work here?Claim your company
Industries
Company Size
51-200
Company Stage
N/A
Total Funding
$19B
Headquarters
Greenwich, Connecticut
Founded
1999
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$19B
Above
Industry Average
Funded Over
0 Rounds
Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing orally bioavailable, small molecule therapies for musculoskeletal diseases, toda...
TriGemX Bio, a New York City-based biotechnology company focused on migraine treatment, raised $94 million in funding. The round was co-led by The Column Group, TCGX, and Viking Global Investors, with participation from additional investors. The company will use the funds to advance clinical development of elismetrep, its lead program. Elismetrep is a novel, oral TRPM8 channel blocker currently in Phase 3 trials for acute migraine treatment. Led by chief executive officer Jeff Goater, TriGemX Bio develops medicines by leveraging insights into neural signalling pathways. The platform focuses on targeting migraine-relevant neural structures such as the trigeminal ganglion to deliver therapies for affected patients. The company was formerly known as Kallyope.
Ecovative Design LLC, the eco-friendly materials company based in Green Island, NY, announced it initially closed on a Series E round of over $30 million.
DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of dermatological indications, today anno...
Pearl Health has raised $110 million to expand its AI platform for managing Medicare patient care. The funding comprises a $50 million equity round led by Andreessen Horowitz, with participation from Viking Global Investors, AlleyCorp and Ulysses Capital, plus a $60 million debt facility from Trinity Capital. The company reached profitability in 2025 and projects $500 million in gross healthcare system savings whilst tripling its patient base from 2024 through end-2026. Pearl's platform helps providers predict risk and automate workflows before issues become emergencies. Pearl supports over 10,000 providers across 40 states, caring for more than 250,000 Medicare beneficiaries. It manages approximately $3.6 billion in annualised medical spend, up from $2.4 billion the previous year.
Find jobs on Simplify and start your career today
Industries
Company Size
51-200
Company Stage
N/A
Total Funding
$19B
Headquarters
Greenwich, Connecticut
Founded
1999
Find jobs on Simplify and start your career today